Lebrikizumab has shown long-term efficacy in patients with moderate-to-severe atopic dermatitis (AD), according to a study presented at a dermatology conference. The study included adults and adolescents who were treated with lebrikizumab for up to three years. Results showed that a high percentage of patients maintained improvement in their skin condition with lebrikizumab treatment, with a low percentage requiring additional therapy. The study was funded by the manufacturer of lebrikizumab, with researchers concluding that the treatment had durable efficacy and a consistent safety profile.
Source link
Long-term efficacy for lebrikizumab seen in moderate, severe eczema
